Latest News

Explore PREVENT Risk Equations reshaping hypertension care, HFpEF therapy, and CKD-related hyperkalemia.

Collaborative practice agreements expand pharmacists’ clinical authority and patient access.

Flexibility, priorities, and structure are just as important as your account balance.

Targeted menin inhibitors offer new hope for patients with difficult-to-treat acute leukemias.

Linvoseltamab joins 3 other bispecific T-cell–engaging antibodies in multiple myeloma, offering deep and durable responses in heavily pretreated patients.

The approval for the oral, fixed-duration chronic lymphocytic leukemia (CLL) regimen was based on results from the phase 3 AMPLIFY trial.

Pharmacy technicians drive patient care through smart, tech-enabled inventory management.

Regulators should engage peptides through science-driven, pharmacy-centered oversight.

A new 4-pillar framework blends AI, real-time PDMP data, and social determinants of health to spot opioid misuse earlier and reduce overdoses.

FDA approves encorafenib plus cetuximab chemotherapy for BRAF V600E metastatic colorectal cancer, boosting survival and response in BREAKWATER.

FDA clears pegzilarginase-nbln enzyme therapy for ARG1-D, cutting toxic arginine and boosting mobility.

HER2 breast cancer vaccine boosted by CD27 sparked durable CD4 memory and dramatic tumor regression in studies.

See how prior authorization delays hit pharmacies first, and what state reforms—continuity rules, gold carding, ePA—can protect patient access.

FDA approves once-daily oral Wegovy for weight loss and long-term maintenance, matching injectable results while cutting cardiovascular event risk.

FDA clears oral Wegovy pills for weight loss, while Lemme Burn Gummies tout metabolic support; plus new thalassemia anemia drug and Lucentis biosimilar.

Study authors suggest that VA and health care professionals should educate patients on the medical evidence, gaps, policies, and laws related to cannabis.

With this action, dupilumab has become the first and only FDA-approved treatment for allergic fungal rhinosinusitis.

The guideline establishes a novel clinical classification framework and recommends direct oral anticoagulants over vitamin K antagonists for eligible patients.

Canada’s experience demonstrates the risks of sidelining pharmacy in medical cannabis policy.

Oncology pharmacists discuss the transformative role of bispecific antibodies in treating relapsed/refractory multiple myeloma, addressing challenges and patient care strategies.

System-based safeguards reduce errors and harm from high-alert medications.